The FDA has identified increased mortality rates linked to two CAR-T therapies: Carvykti, made by Janssen Biotech, and Abecma, from Bristol-Myers Squibb K.K.

Pharmacies and healthcare providers may no longer dispense Paxlovid labeled in accordance with the FDA's emergency use authorization, the agency said March 13.

Drug, supply and equipment shortages are the eighth-most urgent patient safety concern, the ECRI said March 11. 

Par Pharmaceutical, an Endo International company, recalled one lot of treprostinil injection solutions because of the potential presence of silicone particles, the FDA said March 12. 

Eli Lilly has tapped Amazon Pharmacy as a partner to deliver select medications including weight loss drugs directly to consumers' homes.

Seattle Children's is the first FDA-authorized site to deliver an experimental CAR T-cell therapy to children with lupus, the system said March 11. 

A new report from Healthsperien, prepared for the American Hospital Association, found that while the 340B program is still a minor portion of the drug industry revenue, its growth has provided significant benefits to a large number of underserved U.S. patients and communities.

The American Society of Health-System Pharmacists is leading a national search for an executive director to helm the End Drug Shortages Alliance. 

A phase 3 study of Amylyx Pharmaceuticals' approved therapy for amyotrophic lateral sclerosis, Relyvrio, failed to find significant efficacy results. By mid-June, the drugmaker might withdraw the drug. 

Pfizer's shortage of penicillin G benzathine injection, an antibiotic for syphilis and other bacterial infections, is now predicted to last until the end of 2024. 

Compared to 2018, the average diabetes patient now spends 129% more for their medications — largely affecting patients taking GLP-1s like Ozempic and Mounjaro, according to GoodRx. 

National clinical guidelines don't mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of Health-System Pharmacists reported March 6. 

Wegovy, Novo Nordisk's weight loss therapy part of a popular drug class, is now approved for reducing the risk of cardiovascular death, heart attack and stroke in adults who have cardiovascular disease and are either obese or overweight, the FDA said March 8. 

It's past time to support pharmacists during times of crisis and patient care failures, which can cause second victim syndrome, according to American Pharmacists Association CEO Michael Hogue, PharmD. 

The FDA has informed Eli Lilly that it plans to convene a panel of independent experts to learn more about the safety and efficacy of donanemab, the company's proposed Alzheimer's drug. The move delays an FDA decision on the drug until at least later this year.

Two years after launching a company with a few dozen discounted generics, Mark Cuban's Cost Plus Drugs now offers more than 2,000 medications, partners with hundreds of independent and grocery chain pharmacies, and manufactures its own drugs. 

Nirsevimab, a new monoclonal antibody treatment for respiratory syncytial virus, was 90% effective at preventing hospitalizations among infants this virus season, according to a March 7 CDC report.

Boehringer Ingelheim will cap out-of-pocket costs for its inhaler products at $35 per month starting in June. 

Trials for experimental HIV vaccines have been fruitless for the last two decades, but recent scientific advances are spurring optimism among researchers, NBC News reported March 6. 

On March 7, Franklin, Tenn.-based Community Health Systems became the first hospital system to partner with and buy medicines manufactured by Mark Cuban Cost Plus Drug Co.